In principle, low molecular weight compounds could be used as alternatives to antibodies for tumor targeting applications. Our proprietary DNA-Encoded Chemical Libraries greatly facilitate the hit discovery process from millions of molecules. In analogy to Antibody-Drug Conjugates (ADCs), Small Molecule-Drug Conjugates (SMDCs) feature cytotoxic drugs and other payloads which are selectively guided to the disease site by small molecule ligands.
SMALL MOLECULE-DRUG CONJUGATES At Philogen we have identified and patented a number of pathology-associated targets, their corresponding ligands and appropriate linkers for the development of SMDCs.


Cazzamalli (2016) Mol. Cancer Ther. DOI: 10.1158/1535-7163.MCT-16-0283;
Casi & Neri (2015) J Med Chem. 58:8751-61 Review;
Krall et al. (2014) Angew. Chem. Int. Ed. 53:4231-5;
Krall et al. (2014) Chem. Sci. 5:3640-4;
Krall et al. (2013) Angew Chem Int Ed Engl. 52:1384-402 Review;
Müller et al. (2013) J Nucl Med. 54:124-31;
Ahlskog et al. (2009) Bioorg. Med. Chem. Lett. 19:4581-6;
Dumelin et al. (2008) Angew Chem Int Ed Engl. 47:3196-201

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy